INTRODUCTION
Chronic kidney disease-mineral bone disorder (CKD-MBD) was coined in 2006 by the kidney disease improving global outcomes (KDIGO) working group in recognition that the mineral and skeletal disorders caused by CKD are critical contributors to the high cardiovascular morbidity and mortality seen in patients with kidney disease. The typical biochemical profile of altered mineral metabolism includes early and progressive fibroblast growth factor 23 (FGF-23) elevation, decreasing calcitriol, increasing parathyroid hormone, and a gradual rise in phosphate, with associated bone disease, vascular calcification, and left ventricular hypertrophy. Despite extensive research and compelling observational studies, no large-scale randomized controlled trial modifying these factors has shown clinical benefit, and clinical guidelines were developed where little evidence exists. There is a significant need to describe and modify the morbidity and mortality related to CKD-MBD. This review will focus on developments in the management of CKD-MBD over the past year. It will not discuss advances in CKD-MBD in transplant or pediatric patients.
HYPERPHOSPHATEMIA Current KDIGO guidelines for the management of hyperphosphatemia include reduced phosphate intake and oral phosphate binding medications. It is assumed that reduced phosphate intake will benefit CKD and end stage renal disease (ESRD) patients equally, though Selamet et al. [1 excretion (a surrogate for oral phosphate intake) and all-cause mortality in predialysis patients, suggesting that phosphate intake is not directly linked to serum phosphate levels as it is in dialysis patients. Despite widespread use of oral phosphate binding medications, no clinical trial data support benefits for bone strength, cardiovascular events or death [2] . Observational studies suggest that noncalcium binders minimize vascular calcification, but again clinical trial data are lacking. A new class of iron based phosphate binders offers the potential for both phosphate and iron management. Van 
KEY POINTS
CKD-related mineral bone disorders contribute to the high cardiovascular morbidity and mortality seen in patients with CKD and ESRD.
A number of observational studies have defined associations with changes in CKD-MBD parameters and improved clinical outcomes, though clinical trials have yet to prove causality in most cases.
There is a need for new clinical trials that can account for the increasing complexity of the CKD-MBD axis and intervene on more than one pathway. reduced fracture risk [10] . With limited novel therapies that improve dialysis survival, larger studies appear worth pursuing to determine if nutritional supplementation of vitamin D leads to clinical benefit. Arguing that prior associations were not causal, two clinical trials [11,12 & ] were unable to show a reduction in blood pressure in hypertensive patients with oral vitamin D supplementation. In accordance with the PRIMO study [13] , Wang et al. [14] found no difference in left ventricular mass in patients using paricalcitol in stage 3-5 CKD. Suggesting that endothelial dysfunction is at least partially reversible in CKD patients and vitamin D supplementation may yet exert favorable effects on FGF23 is regulated by a number of factors and acts to increase urinary phosphate excretion, inhibit hydroxylation of 25(OH)D and is associated with cardiovascular morbidity. Some have proposed FGF23 as an early biomarker of CKD. In contrast to serum phosphate, FGF23 levels do not vary within individuals during the day or with shortterm variations in dietary intake. Rebholz et al. [19 & ] found that baseline elevation of FGF23 was associated with a five-fold increased risk of ESRD, independent of baseline kidney function and hyperphosphatemia. The association of elevated FGF23 with future ESRD persisted in patients with an estimated glomerular filtration rate more than 90 ml/ min/1.73 m 2 . Similarly, Speer et al. [20] report that a preoperative FGF-23 level predicted mortality in a prospective cohort of 859 patients scheduled for elective cardiac surgery, with FGF23 outperforming the 18 variable EuroSCORE II system. Although neither of these studies proves causation, baseline FGF23 level may have utility as a biomarker in specific circumstances.
It remains unclear if FGF23 is a marker of phosphate excess, a marker of Klotho deficiency, or if FGF23 directly promotes left ventricular hypertrophy and vascular calcification. In a secondary analysis of the EVOLVE trial [EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events], Moe et al. [21] report that cinacalcet use resulted in a more frequent reduction in FGF23 at 20 weeks (68 vs. 28%) compared with control. Among patients on cinacalcet, those with at least a 30% reduction in FGF23 had reduced cardiovascular death and cardiovascular events (interestingly, patients in the control group with > ¼ 30% reduction in FGF23 did not). As the study was not designed to assess causality, additional studies in humans targeting FGF-23 levels appear warranted. Accordingly, Isakova et al. [22 && ] proposed the COMBINE (The CKD Optimal Management With Binders and NicotinamidE) study to determine if reduced dietary phosphate, nicotinamide (aimed to counteract NPT2b upregulation with phosphate binder use), and lanthanum carbonate will safely reduce serum phosphate and FGF23 levels in patients with stage 3-4 CKD. Of note, an experimental human antibody to FGF23 successfully increased phosphate and 1,25(OH)D in patients with X linked hypophosphatemia, and may have future utility if reduction of FGF23 levels improves clinical outcomes [23] . However, there are currently no clinical trial data to recommend active reduction of FGF23.
SECONDARY HYPERPARATHYROIDISM
Secondary hyperparathyroidism (SHPT) is associated with high-turnover bone disease and possibly increased mortality. Available therapy for SHPT includes phosphate binders, vitamin D receptor activators, calcimimetics, and surgical parathyroidectomy. In 2009, the KDIGO guidelines suggested the maintenance of phosphorus and calcium in the normal range and serum parathyroid hormone (PTH) in the range of two to nine times the upper limit of normal. In a prospective study of $6300 European dialysis patients, Fernandez-Martin et al. [24 && ] found that serum phosphate, calcium, and PTH were all associated with increased mortality with a U shaped curve. Importantly, in patients with serum phosphate more than 5.2 mg/dl or serum Ca more than 9.5 mg/dl, decreases toward the 'safest ranges' were associated with a lower relative risk of mortality, one of the first demonstrations that active reduction in serum phosphate leads to decreased mortality. Tentori et al. [25 && ] analyzed data from the Dialysis Outcomes and Practice Patterns Study to assess trends in PTH and SHPT therapies over the past 15 years. Compared with PTH 150-300 pg/ml, all-cause mortality was higher for PTH 301-450 pg/ml and greater than 600 pg/ml, with PTH greater than 600 pg/ml also associated with an increased risk of cardiovascular mortality and cardiovascular hospitalizations. PTH less than 50 pg/ml was associated with adverse outcomes and a high proportion of these patients were continued on therapy for SHPT, increasing their risk of adynamic bone disease. With a suggestion that a PTH more than 300 ng/ml is associated with increased risk of death and hospitalization, the trend toward increased PTH in dialysis patients worldwide may have clinical consequences.
The European Renal Best Practice group recently released recommendations against the routine use of calcimimetic therapy in dialysis patients [26] noting that treating 1000 people with cinacalcet for 1 year has no effect on mortality, prevents three patients from surgical parathyroidectomy and leads to $60 episodes of hypocalcemia and $150 episodes of nausea. However, in a prespecified age based subgroup analysis of the EVOLVE trial, Parfrey et al. [27 && ] reported a reduced risk of death and major cardiovascular events in older (age >65), but not younger, dialysis patients on cinacalcet. In summary, although cinacalcet was not formally proven to improve cardiovascular or all-cause mortality, neither has a positive effect been formally ruled out [28, 29] . Cinacalcet continues to be used for the management of SHPT and its secondary effects on bone in ESRD. In the PARA-DIGM trial, Wetmore et al. [30] noted only modest reductions in PTH with cinacalcet (À12%) and vitamin D analogs (À7%) as monotherapy. In an exploratory analysis of PARADIGM, cinacalcet use was associated with hypocalcemia and reduced FGF-23, whereas vitamin D analogs were associated with hypercalcemia, hyperphosphatemia, and increased FGF23 [31] . Finally, administration of a novel IV calcimimetic (AMG-416), yet to be approved by the FDA, resulted in significant PTH reductions, with over 50% of dialysis patients experiencing a more than 30% decrease [32] . If larger studies do not implicate unwanted side effects, AMG-416 may prove useful for the management of SHPT in dialysis patients.
In the setting of a PTH more than 600 ng/ml despite medical therapy, many consider surgical parathyroidectomy. Komaba et al. [33 & ] reported a 34 and 41% lower risk for 1 year all-cause and cardiovascular mortality, respectively, following parathyroidectomy in $4500 Japanese dialysis patients. A nested index-referent study of Swedish dialysis patients also noted a reduced risk of death following parathyroidectomy [34] , whereas a United States Renal Database System study identified a 2% 30-day mortality and a 24% rehospitalization rate (30% of these required ICU care) within 30 days of discharge following parathyroidectomy [35 && ]. Differences in the overall health of the various populations (more diabetes in the US population for example) may partially explain the disparate results described above and selection bias is a concern in retrospective studies. It may be that older, sicker patients benefit more from cinacalcet than parathyroidectomy, consistent with the recent subgroup analysis of the EVOLVE trial [27 && ].
CALCIPHYLAXIS
Calciphylaxis (also known as calcific uremic arteriolopathy) is a rare condition seen in patients with advanced kidney disease that is associated with high morbidity and mortality [36, 37] . The current understanding of the pathogenesis and risk factors of calciphylaxis is limited and unfortunately, at present, there are no effective and well-studied prevention or treatment strategies. The annual incidence of calciphylaxis is less than 1% in chronic hemodialysis patients; however the frequency of calciphylaxis may be on the rise [38] . The proposed calciphylaxis risk factors are summarized in Table 2 . A multimodal and multidisciplinary approach that incorporates wound and pain management, sodium thiosulfate, optimization of mineral bone parameters, bisphosphonates, and avoidance of risk factors such as vitamin K antagonist has been advocated in the latest reports, and this approach is described in detail in a recent review by Nigwekar [36] . A recent case series of 46 calciphylaxis patients has reported the efficacy of hyperbaric oxygen therapy in over 50% of calciphylaxis patients when it was added as a 'last resort' therapy after failure to respond to other potential therapies [39] . It is also noteworthy that the EVOLVE trial demonstrated a relative calciphylaxis risk reduction of 69-75% in the cinacalcet arm compared with the placebo arm [40] ; however, the low event rate of calciphylaxis introduces a possibility that findings may have been because of chance.
FRACTURE AND RENAL OSTEODYSTROPHY
ESRD is associated with a two to four-fold increase in fracture risk compared with the general population and the incidence of fracture in the CKD population is increasing. Current strategies to minimize fracture risk focus normalizing levels of calcium, phosphorus, PTH and 25(OH)D, and consideration of available bone modifying therapies. Tetracycline labeled bone biopsy remains the gold standard for classification of bone disease in CKD, though less invasive methods are needed. A number of recent studies showed utility of DEXA scans in patients with CKD causing KDIGO to reexamine recommendations regarding routine BMD testing [41] . Haarhaus et al. [42 & ] report that increased levels of the bone alkaline phosphatase (bALP) isoform B1x (exclusively found in patients with CKD) are diagnostic of biopsy proven low bone turnover, whereas elevated levels of bALP and PTH are suggestive of non-low bone turnover. Dickkopf-related protein 1 (DKK1) and sclerostin (a Wnt inhibitor) [43] may be additional biomarkers for CKD-MBD, but widespread use of bALP isoform B1x, DKK1, and sclerostin is currently limited by assay availability and reliability.
Behets et al. [44 && ] characterized bone histology after treatment with cinacalcet in dialysis patients with biopsy proven high-turnover bone disease, noting improvement in bone formation and biochemical markers. Although no patient had normal bone histology at baseline, 20/77 patients had a normal bone biopsy after 12 months of cinacalcet use. A number of therapeutic agents for the management of bone disease now exist, including anabolic (teriparatide, romosozumab) or antiresorptive (bisphosphonates, denosumab) drugs, though limited data exist on the antifracture efficacy (and sometimes safety) of these agents in CKD populations. Palcu et al. [45] reported well tolerated use of teriparatide over 24 months in a single dialysis patient with improvement in pain, bone biopsy, and BMD. In a retrospective study of 13 patients with CKD4-5 treated with denosumab, Dave et al. [46] identified severe hypocalcemia in 8/13 patients. A prospective study of denosumab in 11 dialysis patients with low bone mass identified an increase in BMD following one dose of denosumab, complicated only by asymptomatic hypocalcemia and a compensatory increase in PTH [47] . Both of these studies were observational and small, but suggest that denosumab might be well tolerated for use in dialysis patients with aggressive repletion of calcium and vitamin D. Finally, the sclerostin inhibitor romosozumab is an exciting new agent that improved bone mineral density via both bone formation and decreased bone resorption over 12 months in postmenopausal women, though utility in patients with CKD is unknown [48] . Overall, despite reasonable consensus that these agents may be used in patients with CKD1-3, use in more advanced CKD requires additional study and close monitoring [41, 49] .
CONCLUSIONS
Significant effort is placed on the management of CKD-MBD, yet many questions remain. The current KDIGO guidelines remain the standard of care, though evidence to support many of the recommendations is poor and begs for additional clinical trials. As past discoveries resulted in the rebranding of the field (CKD-MBD), the current multitude of interrelated factors in CKD-MBD requires novel investigative methodologies. Instead of focusing on the perturbation of one or two substrates (which often leads to unwanted alterations of other related parameters), future studies will need to measure all of these molecules simultaneously and likely intervene on multiple pathways to produce a desired clinical effect. Methodologies borrowed from systems biology and pathway or network analysis are likely to be of benefit as they are able to incorporate the increasing complexity of CKD-MBD.
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